Previous Close | 32.08 |
Open | 31.57 |
Bid | 32.30 x 1000 |
Ask | 33.35 x 800 |
Day's Range | 30.69 - 32.80 |
52 Week Range | 16.07 - 59.24 |
Volume | |
Avg. Volume | 787,938 |
Market Cap | 2.324B |
Beta (5Y Monthly) | 1.58 |
PE Ratio (TTM) | 57.61 |
EPS (TTM) | 0.56 |
Earnings Date | Feb 26, 2024 - Mar 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 47.20 |
Subscribe to Yahoo Finance Plus to view Fair Value for SDGR
NEW YORK, November 17, 2023--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on November 13, 2023, the company granted (i) non-statutory stock options to purchase 14,400 shares of the company’s common stock to nine newly hired employees and (ii) restricted stock units (RSUs) with respect to 10,050 shares of the company’s common stock to 13 newly hired employees. These grants were m
Ahead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks. Fundamentally, the reasoning centers on relative insulation. Of course, no sector is ever fully insulated from the equity sector’s ebb and flow. And even established blue chips may suffer volatility if the major indices print red ink. However, certain compelling biotech stocks to buy offer overwhelming relevance. Irrespective of economic conditions, society will likely
We’re still in the initial stages of a massively disruptive artificial intelligence (AI) boom. Big Tech is investing billions of dollars into it. Grand View Research saying we could be looking at a $1.8 trillion opportunity by 2030. And so far, it’s changing just about everything about everything. That includes healthcare–which could create a $188 billion opportunity by 2030, according to analysts at Statista. Not only is AI assisting with diagnoses and clinical outcomes, but it’s also helping w